Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07062119 IN PATIENTS WITH ADVANCED GASTROINTESTINAL TUMORS

NCT04171141 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04171141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04171141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07062119 IN PATIENTS WITH ADVANCED GASTROINTESTINAL TUMORS
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Terminated
Start date
November 19, 2019
Completion date
November 28, 2023
Enrollment
79 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal adenocarcinomas, esophageal adenocarcinomas, gastric adenocarcinomas, gastrointestinal tumors